NASDAQ : PCRX
Pacira BioSciences, Inc. — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Last price 36.39 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.45B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.45B |
| Enterprise Value | 1.61B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 39.86M |
| Shares Outstanding | 39.86M |
| Shares Change (YoY) | -7.82% |
| Shares Change (QoQ) | -1.49% |
| Owned by Insiders (%) | 1.81% |
| Owned by Institutions (%) | 106.63% |
| Float | 39.13M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 103.45 |
| Forward PE | 11.78 |
| PS Ratio | 1.94 |
| Forward PS | 1.91 |
| PB Ratio | 2.16 |
| P/TBV Ratio | 3.95 |
| P/FCF Ratio | 8.08 |
| P/OCF Ratio | 7.73 |
| PEG Ratio | 1.18 |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 110.10 |
| EV / Sales | 2.16 |
| EV / EBITDA | 13.00 |
| EV / EBIT | 49.09 |
| EV / FCF | 8.98 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.04 |
| Quick Ratio | 3.21 |
| Debt / Equity | 0.61 |
| Debt / EBITDA | 2.97 |
| Debt / FCF | 2.30 |
| Interest Coverage | 2.12 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 2.05% |
| Return on Assets (ROA) | 1.48% |
| Return on Invested Capital (ROIC) | 3.21% |
| Return on Capital Employed (ROCE) | 2.93% |
| Weighted Average Cost of Capital (WACC) | 5.08% |
| Revenue Per Employee | $900,077 |
| Profits Per Employee | $17,657 |
| Employee Count | 829 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 1.10 |
Taxes
| Measure | Value |
|---|
| Income Tax | 3.01M |
| Effective Tax Rate | 17.06% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.25 |
| 52-Week Price Change | +73.20% |
| 50-Day Moving Average | 29.06 |
| 200-Day Moving Average | 24.84 |
| Relative Strength Index (RSI) | 83.22 |
| Average Volume (20 Days) | 2,680,585 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 4.26M |
| Short Previous Month | 8.08M |
| Short % of Shares Out | 10.69% |
| Short % of Float | 10.89% |
| Short Ratio (days to cover) | 1.89 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 746.16M |
| Gross Profit | 591.01M |
| Operating Income | 32.83M |
| Pretax Income | 17.65M |
| Net Income | 14.64M |
| EBITDA | 123.97M |
| EBIT | 32.83M |
| Earnings Per Share (EPS) | $0.35 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 251.03M |
| Total Debt | 412.12M |
| Net Cash | -161.09M |
| Net Cash Per Share | -$4.04 |
| Equity (Book Value) | 671.98M |
| Book Value Per Share | 16.87 |
| Working Capital | 493.20M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 187.66M |
| Capital Expenditures | -8.15M |
| Depreciation & Amortization | 91.14M |
| Net Borrowing | -220.24M |
| Free Cash Flow | 179.52M |
| FCF Per Share | $4.50 |
Margins
| Measure | Value |
|---|
| Gross Margin | 79.21% |
| Operating Margin | 4.40% |
| Pretax Margin | 2.37% |
| Profit Margin | 1.96% |
| EBITDA Margin | 16.61% |
| EBIT Margin | 4.40% |
| FCF Margin | 24.06% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 7.82% |
| Shareholder Yield | 7.82% |
| Earnings Yield | 0.97% |
| FCF Yield | 12.38% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $33.57 |
| Price Target Difference | -7.75% |
| Analyst Consensus | Hold |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 6.74% |
| EPS Growth Forecast (3Y) | 18.64% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 2 |
| Piotroski F-Score | 8 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |